HCL
MCID: HRY003
MIFTS: 57

Hairy Cell Leukemia (HCL) malady

Categories: Rare diseases, Cancer diseases, Blood diseases, Immune diseases

Aliases & Classifications for Hairy Cell Leukemia

Aliases & Descriptions for Hairy Cell Leukemia:

Name: Hairy Cell Leukemia 12 50 56 14 69
Hairy Cell Leukemia Variant 12 56 29 69
Hcl-V 12 56 14
Leukemic Reticuloendotheliosis 50 56
Hcl 50 56
Prolymphocytic Variant of Hairy Cell Leukemia 56
Leukemic Reticuloendotheliosis Variant 56
Prolymphocytic Variant of Hcl 56
Hairy Cell Leukaemia Variant 12
Leukemia, Hairy Cell 42
Leukemia Hairy Cell 52

Characteristics:

Orphanet epidemiological data:

56
hairy cell leukemia
Prevalence: 1-9/1000000 (Europe),1-9/100000 (Europe),1-9/1000000 (United States); Age of onset: Adult;
hairy cell leukemia variant
Inheritance: Multigenic/multifactorial; Prevalence: 1-9/1000000 (United States); Age of onset: Adult; Age of death: adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:285 DOID:713
ICD10 33 C91.4 C91.40
ICD9CM 35 202.4
MeSH 42 D007943
NCIt 47 C7402 C7401
UMLS via Orphanet 70 C0349633 C0023443
ICD10 via Orphanet 34 C91.4
MESH via Orphanet 43 D007943

Summaries for Hairy Cell Leukemia

NIH Rare Diseases : 50 hairy cell leukemia is a rare, slow-growing cancer of the blood in which the bone marrow makes too many b cells (lymphocytes), a type of white blood cell that fights infection. the condition is named after these excess b cells which look 'hairy' under a microscope. as the number of leukemia cells increases, fewer healthy white blood cells, red blood cells and platelets are produced. the underlying cause of this condition is unknown. while there is no cure, treatment can lead to remission which can last for years.   last updated: 4/3/2012

MalaCards based summary : Hairy Cell Leukemia, also known as hairy cell leukemia variant, is related to refractory hairy cell leukemia and intrapelvic lymph node leukemic reticuloendotheliosis. An important gene associated with Hairy Cell Leukemia is BRAF (B-Raf Proto-Oncogene, Serine/Threonine Kinase), and among its related pathways/superpathways are Innate Immune System and Apoptotic Pathways in Synovial Fibroblasts. The drugs Doxil and Gemzar have been mentioned in the context of this disorder. Affiliated tissues include b cells, bone and bone marrow, and related phenotypes are hematopoietic system and digestive/alimentary

Disease Ontology : 12 A chronic lymphocytic leukemia that is characterized by over production of B cells (lymphocytes) by the bone marrow where the B cells appear hairy under a microscope.

Wikipedia : 71 Hairy cell leukemia is an uncommon hematological malignancy characterized by an accumulation of abnormal... more...

Related Diseases for Hairy Cell Leukemia

Diseases related to Hairy Cell Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 128)
id Related Disease Score Top Affiliating Genes
1 refractory hairy cell leukemia 12.2
2 intrapelvic lymph node leukemic reticuloendotheliosis 12.2
3 splenic manifestation of hairy cell leukemia 12.0
4 leukemia 11.1
5 gastrinoma 11.0
6 mycobacterium avium complex disease 11.0
7 lymphoma 10.4
8 chronic lymphocytic leukemia 10.3
9 malignant glioma 10.3 IFNA1 IFNA2
10 endometrial small cell carcinoma 10.2 ACP5 BRAF CD22
11 ceruminoma 10.2 IFNA1 IFNA2
12 benign exophthalmos syndrome 10.2 IFNA1 IFNB1
13 acute dacryoadenitis 10.2 IFNA1 IL2 IL3
14 multiple carboxylase deficiency 10.2 IFNA1 IL2 IL2RA
15 childhood choriocarcinoma of the testis 10.2 ADA IL2 IL2RA
16 b-cell lymphomas 10.1
17 birth defects 10.1 IFNA1 IL2RA IL3
18 myeloid leukemia 10.1
19 erythrocytosis, somatic 10.1 IFNA1 IFNA2 IL3
20 vasculitis 10.1
21 prolymphocytic leukemia 10.1
22 anterior foramen magnum meningioma 10.1 ADA IFNA1 IFNA2 IL2 IL2RA
23 pre-malignant neoplasm 10.1 IFNA1 IL2 IL2RA
24 goodpasture syndrome 10.0 ADA IFNA1 IFNA2 IL2 IL2RA
25 exophthalmos 10.0 IFNA1 IFNA2 IFNB1 IL2
26 sarcoma 10.0
27 coarctation of aorta 10.0 IFNA1 IFNA2 IL2 IL2RA ITGAE
28 chondrodysplasia punctata, tibia-metacarpal type 10.0 CD5 IFNA1 IFNA2
29 hyperparathyroidism 10.0
30 advanced sleep phase syndrome, familial, 1 10.0 IFNA1 IFNB1 IL2 IL2RA
31 polycythemia 10.0
32 splenomegaly 10.0
33 hodgkin lymphoma 10.0
34 inclusion conjunctivitis 10.0 CD22 CD5 IL2
35 hyperaldosteronism, familial, type ii 10.0 CD5 IL2 IL2RA
36 vasculopathy, retinal, with cerebral leukodystrophy 9.9 ACP5 IFNB1 IL3RA
37 fallopian tube endometriosis 9.9 IL2 IL2RA IL3
38 bernard-soulier syndrome, type c 9.9 BRAF IFNA1 IFNA2 IL2 MAP2K1
39 hemophagocytic lymphohistiocytosis 9.9 IL2 IL2RA IL3 IL3RA
40 seminal vesicle chronic gonorrhea 9.9 ADA CCND1 CD5
41 meningitis 9.9
42 autoimmune hemolytic anemia 9.9
43 hemolytic anemia 9.9
44 mantle cell lymphoma 9.9
45 myelofibrosis 9.9
46 splenic marginal zone lymphoma 9.9
47 theileriasis 9.9 CCND1 CD5 IL2
48 guillain-barre syndrome 9.8
49 adenocarcinoma 9.8
50 large granular lymphocyte leukemia 9.8

Graphical network of the top 20 diseases related to Hairy Cell Leukemia:



Diseases related to Hairy Cell Leukemia

Symptoms & Phenotypes for Hairy Cell Leukemia

MGI Mouse Phenotypes related to Hairy Cell Leukemia:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.73 ADA ANXA1 BRAF CCND1 CD22 CD5
2 digestive/alimentary MP:0005381 9.7 ADA ANXA1 BRAF CCND1 IL2 IL2RA
3 immune system MP:0005387 9.4 ADA ANXA1 BRAF CCND1 CD22 CD5

Drugs & Therapeutics for Hairy Cell Leukemia

FDA approved drugs:

(show all 11)
id Drug Name Active Ingredient(s) 17 Company Approval Date
1
Doxil 17 46 DOXORUBICIN HYDROCHLORIDE Alza Approved June 1999
2
Gemzar 17 46 GEMCITABINE HYDROCHLORIDE Eli Lilly Approved May 1996
3
Intron A 17 46 INTERFERON ALFA-2B Schering-Plough Approved December 1997/ Approved December 1995/ Approved March 1997
4
Sensipar 17 CINACALCET HYDROCHLORIDE Amgen Approved March 2004
5
Treanda 17 46 BENDAMUSTINE HYDROCHLORIDE Cephalon Approved October 2008
6
UroXatral 17 ALFUZOSIN HYDROCHLORIDE Sanofi-aventis Approved June 2003
7
Valchlor 17 MECHLORETHAMINE HYDROCHLORIDE Ceptaris Therapeutics Approved August 2013
8
Zuplenz 17 ONDANSETRON Strativa Pharmaceuticals Approved July 2010
9
Patanase 17 OLOPATADINE HYDROCHLORIDE Alcon Approved April 2008
10
Xopenex 17 LEVALBUTEROL HYDROCHLORIDE Sepracor Approved February 2002
11
Zyrtec 17 CETIRIZINE HYDROCHLORIDE Pfizer Approved December 1995

Drugs for Hairy Cell Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 316)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cefepime Approved Phase 3 88040-23-7 5479537
2
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
3
Ofloxacin Approved Phase 3 82419-36-1 4583
4
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
5
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Early Phase 1 50-18-0, 6055-19-2 2907
6
Cladribine Approved, Investigational Phase 3,Phase 2,Phase 1 4291-63-8 20279
7
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
8
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
9
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
10
Guaifenesin Approved, Vet_approved Phase 3,Phase 2 93-14-1 3516
11
Morphine Approved, Investigational Phase 3 57-27-2 5288826
12
Ondansetron Approved Phase 3,Phase 2 99614-02-5 4595
13
Dalteparin Approved Phase 3 9041-08-1
14
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
15
Piperacillin Approved Phase 3 66258-76-2 43672
16
Tazobactam Approved Phase 3 89786-04-9 123630
17
Vancomycin Approved Phase 3 1404-90-6 441141 14969
18
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
19
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
20
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
21
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
22
Captopril Approved Phase 3 62571-86-2 44093
23
Fluconazole Approved Phase 3 86386-73-4 3365
24
Itraconazole Approved, Investigational Phase 3 84625-61-6 55283
25
Palivizumab Approved, Investigational Phase 3 188039-54-5
26
Ribavirin Approved Phase 3 36791-04-5 37542
27
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757 53477783
28
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
29
Moxifloxacin Approved, Investigational Phase 3 354812-41-2, 151096-09-2 152946
30
Norgestimate Approved Phase 3 35189-28-7 6540478
31
Ginseng Approved, Nutraceutical Phase 3 50647-08-0
32 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
33 Anti-Infective Agents Phase 3,Phase 2,Phase 1
34 Cephalosporins Phase 3
35 Cytochrome P-450 CYP1A2 Inhibitors Phase 3
36 Cytochrome P-450 Enzyme Inhibitors Phase 3,Phase 1,Phase 2
37 Renal Agents Phase 3,Phase 1,Phase 2
38 Topoisomerase Inhibitors Phase 3,Phase 1,Phase 2,Early Phase 1
39 Analgesics Phase 3
40 Anesthetics Phase 3
41 Anesthetics, Dissociative Phase 3
42 Anesthetics, General Phase 3
43 Anesthetics, Intravenous Phase 3
44 Central Nervous System Depressants Phase 3,Phase 2,Phase 1
45 Excitatory Amino Acid Antagonists Phase 3
46 Excitatory Amino Acids Phase 3
47 Neurotransmitter Agents Phase 3,Phase 2
48 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
49 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Early Phase 1
50 Antiviral Agents Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 217)
id Name Status NCT ID Phase
1 Levofloxacin Compared With Cefepime in Treating Cancer Patients With Fever and Neutropenia Unknown status NCT00020865 Phase 3
2 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3
3 Daily or Weekly Cladribine in Treating Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3
4 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3
5 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
6 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3
7 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3
8 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3
9 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
10 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
11 Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count Completed NCT00003805 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3
13 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
14 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3
16 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3
17 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3
18 Captopril in Treating Patients Undergoing Bone Marrow or Stem Cell Transplantation Completed NCT00004230 Phase 3
19 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
20 Itraconazole Compared With Fluconazole to Prevent Infections in Patients Undergoing Peripheral Stem Cell or Bone Marrow Transplantation Completed NCT00003883 Phase 3
21 Ribavirin With or Without Monoclonal Antibody Therapy in Treating Patients Who Develop RSV Pneumonia Following Peripheral Stem Cell Transplantation Completed NCT00014391 Phase 3
22 Therapy Optimisation for the Treatment of Hairy Cell Leukemia Recruiting NCT02131753 Phase 2, Phase 3
23 Moxetumomab Pasudotox for Advanced Hairy Cell Leukemia Active, not recruiting NCT01829711 Phase 3
24 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3
25 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas Unknown status NCT01805037 Phase 1, Phase 2
26 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
27 A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia Completed NCT00001567 Phase 2
28 Treatment of Hairy Cell Leukaemia Variant and Relapsing Hairy Cell Leukaemia With Cladribine Plus Rituximab Completed NCT02157181 Phase 2
29 BL22 Immunotoxin in Treating Patients Previously Treated With Cladribine for Hairy Cell Leukemia Completed NCT00074048 Phase 2
30 Rituximab in Treating Patients With Refractory or Recurrent Hairy Cell Leukemia Following Cladribine Therapy Completed NCT00003757 Phase 2
31 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
32 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2
33 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
34 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2
35 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2
36 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2
37 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors Completed NCT01326702 Phase 1, Phase 2
38 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma Completed NCT01258998 Phase 2
39 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2
40 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies Completed NCT01789255 Phase 2
41 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
42 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
43 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2
44 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2
45 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2
46 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2
47 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis Completed NCT00132015 Phase 2
48 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2
49 Fludarabine, Busulfan, and Antilymphocyte Globulin Followed by Donor Stem Cell Transplant in Treating Older Patients With Hematological Cancer Completed NCT00806767 Phase 2
50 Lymphocyte Infusion in Treating Patients With Relapsed Cancer After Bone Marrow or Peripheral Stem Cell Transplantation Completed NCT00003887 Phase 2

Search NIH Clinical Center for Hairy Cell Leukemia

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: leukemia, hairy cell

Genetic Tests for Hairy Cell Leukemia

Genetic tests related to Hairy Cell Leukemia:

id Genetic test Affiliating Genes
1 Hairy Cell Leukemia 29

Anatomical Context for Hairy Cell Leukemia

MalaCards organs/tissues related to Hairy Cell Leukemia:

39
B Cells, Bone, Bone Marrow, Prostate, T Cells, Liver, Spleen

Publications for Hairy Cell Leukemia

Articles related to Hairy Cell Leukemia:

(show top 50) (show all 699)
id Title Authors Year
1
sIL2R ratio as early marker for response in hairy cell leukemia and the prognostic relevance of IL28B genotype to interferon-I+ therapy. ( 28214980 )
2017
2
Concomitant B Hairy Cell Leukemia and Mycosis Fungoides in an Elderly Man. ( 28512405 )
2017
3
Lymphocytosis, villi, and nucleoli: a variant of hairy cell leukemia. ( 28092880 )
2016
4
Refractory hairy cell leukemia-variant. ( 27727469 )
2016
5
Ibrutinib for relapsed refractory hairy cell leukemia variant. ( 27733095 )
2016
6
Hairy cell leukemia followed by polycythemia vera: report of the first case. ( 26941958 )
2016
7
Neuroendocrine Differentiation of a Primary BRAF Mutant Colon Cancer in a Patient With aA History of Hairy Cell Leukemia. ( 27117521 )
2016
8
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia. ( 27903528 )
2016
9
Composite hairy cell leukemia and chronic lymphocytic leukemia. ( 27685932 )
2016
10
A Unique Hairy Cell Leukemia Variant. ( 27462230 )
2016
11
Detection of activating MAP2K1 mutations in atypical hairy cell leukemia and hairy cell leukemia variant. ( 27241017 )
2016
12
Hairy cell leukemia-variant without typical morphology and with Near-tetraploid DNA Content. ( 27997757 )
2016
13
BRAF inhibition in hairy cell leukemia with low dose vemurafenib. ( 26941398 )
2016
14
Toxoplasmic Encephalitis with Untreated Hairy Cell Leukemia Variant. ( 27803415 )
2016
15
CD10-Positive Hairy Cell Leukemia Involving Multiple Deep Lymph Nodes. ( 27013179 )
2016
16
BRAF-V600E mutation in hairy cell leukemia: from bench to bedside. ( 27554081 )
2016
17
CD27-positive hairy cell leukemia-Japanese variant. ( 26868143 )
2016
18
Long-term treatment of hairy cell leukemia with interferon-I+: still aA viable therapeutic option. ( 27429657 )
2016
19
CD5 positive hairy cell leukemia: A rare case report with brief review of literature. ( 27129891 )
2016
20
BRAF inhibitor: targeted therapy in hairy cell leukemia. ( 27282942 )
2016
21
Audit of compliance with the British Committee for Standards in Haematology (BCSH) revised guidelines for the diagnosis and assessment of treatment response of hairy cell leukemia in University Hospital Galway. ( 27170271 )
2016
22
Leukocytoclastic vasculitis associated with hairy cell leukemia at diagnosis: a case report and review of the literature. ( 27002952 )
2016
23
The Droplet Digital PCR: A New Valid Molecular Approach for the Assessment of B-RAF V600E Mutation in Hairy Cell Leukemia. ( 27790140 )
2016
24
Hairy Cell Leukemia and Bone Pain. ( 26679440 )
2016
25
Response of relapsed central nervous system hairy cell leukemia to vemurafenib. ( 27116997 )
2016
26
Hairy cell leukemia with ascites and coexistent histoplasmosis. ( 25673617 )
2015
27
Plasma cell leukemia mimicking hairy cell leukemia. ( 26013472 )
2015
28
Novel therapeutic options for relapsed hairy cell leukemia. ( 25563425 )
2015
29
Hairy cell leukemia variant: the importance of differential diagnosis. ( 25818826 )
2015
30
Authentic caring occasions for patients in hairy cell leukemia clinical trials. ( 25840397 )
2015
31
Lymphomatous Variant of Hairy Cell Leukemia: a Distinctive Presentation Mimicking Low-Grade B-Cell Lymphoma. ( 25809821 )
2015
32
Requisite analytic and diagnostic performance characteristics for the clinical detection of BRAF V600E in hairy cell leukemia: a comparison of 2 allele-specific PCR assays. ( 24503706 )
2015
33
Hairy cell leukemia: Uncommon clinical features, unusual sites of involvement and some rare associations. ( 26614897 )
2015
34
The importance of the tissue microenvironment in hairy cell leukemia. ( 26614899 )
2015
35
What your hairy cell leukemia patients want you to know. ( 26614905 )
2015
36
Hairy cell leukemia: Past, present and future. ( 26614906 )
2015
37
Correction: CD38 in Hairy Cell Leukemia Is a Marker of Poor Prognosis and a New Target for Therapy. ( 26627642 )
2015
38
Rituximab as frontline monotherapy in untreated hairy cell leukemia patients. ( 25672650 )
2015
39
Immunohistochemistry for BRAF V600E in the Differential Diagnosis of Hairy Cell Leukemia vs Other Splenic B-Cell Lymphomas. ( 26071465 )
2015
40
NFkB is activated by multiple mechanisms in hairy cell leukemia. ( 25960206 )
2015
41
Immunophenotypic aberrancy of a case of hairy cell leukemia. ( 25825575 )
2015
42
Evaluation of allele-specific PCR and immunohistochemistry for the detection of BRAF V600E mutations in hairy cell leukemia. ( 25511147 )
2015
43
Immunoconjugates in the management of hairy cell leukemia. ( 26614902 )
2015
44
Unusual Soft Tissue Infiltrates With 18F-FDG Uptake in a Patient With Hairy Cell Leukemia. ( 25783506 )
2015
45
BRAF V600E and MAP2K1 mutations in hairy cell leukemia and splenic marginal zone lymphoma cases. ( 25729732 )
2015
46
Cotreatment of hairy cell leukemia and melanoma with the BRAF inhibitor dabrafenib. ( 25583765 )
2015
47
Targeting Mutant BRAF in Relapsed or Refractory Hairy-Cell Leukemia. ( 26352686 )
2015
48
The utility of BRAF V600E mutation-specific antibody VE1 for the diagnosis of hairy cell leukemia. ( 25511150 )
2015
49
BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity. ( 25480661 )
2015
50
Hairy Cell Leukemia Presenting with Isolated Skeletal Involvement Successfully Treated by Radiation Therapy and Cladribine: A Case Report and Review of the Literature. ( 26788382 )
2015

Variations for Hairy Cell Leukemia

Expression for Hairy Cell Leukemia

Search GEO for disease gene expression data for Hairy Cell Leukemia.

Pathways for Hairy Cell Leukemia

Pathways related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 42)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.97 ANXA1 BRAF CCND1 CD22 IFNA1 IFNA2
2
Show member pathways
13.83 BRAF IFNA1 IFNA2 IFNB1 IL2 IL2RA
3
Show member pathways
13.64 BRAF IFNA1 IFNA2 IFNB1 IL2 IL2RA
4
Show member pathways
13.43 BRAF IFNA1 IFNA2 IFNB1 IL2 IL2RA
5
Show member pathways
13.28 IFNA1 IFNA2 IFNB1 IL2 IL2RA IL3
6
Show member pathways
13.26 ANXA1 BRAF CCND1 IFNA1 IFNA2 IFNB1
7
Show member pathways
13.02 BRAF IL2 IL2RA IL3 ITGAE ITGAX
8
Show member pathways
12.89 CCND1 IFNA1 IFNA2 IFNB1 IL2 MAP2K1
9
Show member pathways
12.81 CCND1 IFNA1 IFNA2 IL2 IL2RA IL3
10
Show member pathways
12.76 BRAF CCND1 IL2 IL2RA MAP2K1
11
Show member pathways
12.73 CCND1 IFNA1 IFNA2 IFNB1 IL2 IL2RA
12 12.44 CCND1 IFNA1 IFNA2 IFNB1 IL2 IL2RA
13
Show member pathways
12.43 BRAF IFNA1 IFNA2 IFNB1 IL2 IL3
14
Show member pathways
12.3 BRAF IL3 IL3RA MAP2K1
15 12.2 IFNA1 IFNA2 IFNB1 ITGAX
16
Show member pathways
12.12 IL2 IL2RA IL3 IL3RA
17
Show member pathways
12.08 IFNA1 IFNA2 IFNB1 IL2 IL3
18 12.06 CCND1 IL2RA IL3RA ITGAE ITGAX
19 12.03 BRAF IFNA1 IFNA2 IFNB1
20
Show member pathways
12 BRAF IL2 IL2RA MAP2K1
21
Show member pathways
12 CCND1 IFNA1 IFNA2 IFNB1 IL2 IL2RA
22 11.87 BRAF IFNB1 IL3 MAP2K1
23 11.83 BRAF IL2 MAP2K1
24
Show member pathways
11.82 IL3 IL3RA MAP2K1
25 11.82 CD22 CD5 IL2RA IL3 IL3RA
26 11.8 IL2RA IL3RA MAP2K1
27 11.75 IL2 IL2RA ITGAE
28
Show member pathways
11.73 IL2 IL2RA IL3
29 11.71 BRAF CCND1 MAP2K1
30 11.69 BRAF IL2 IL3 ITGAE ITGAX MAP2K1
31 11.68 IFNA2 IFNB1 IL2 IL3RA ITGAE ITGAX
32
Show member pathways
11.62 BRAF IL2 IL2RA MAP2K1
33 11.56 BRAF CCND1 MAP2K1
34 11.54 CD22 CD5 IL3RA
35
Show member pathways
11.45 CCND1 IL2RA MAP2K1
36 11.42 IFNA1 IFNA2 IFNB1
37 11.33 IFNA1 IFNA2 IFNB1 IL2 IL2RA IL3
38 11.29 CD22 CD5 IFNA2 IL2 IL2RA IL3
39 11.23 IFNB1 IL2 IL3
40 11.2 BRAF CCND1 MAP2K1
41
Show member pathways
11.18 IL2 IL2RA MAP2K1
42 10.89 ACP5 IFNB1

GO Terms for Hairy Cell Leukemia

Cellular components related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.02 ADA CD5 IL2RA ITGAE ITGAX

Biological processes related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

(show all 26)
id Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.93 ANXA1 IFNA2 IFNB1 IL2RA
2 adaptive immune response GO:0002250 9.89 ANXA1 IFNA1 IFNB1 IL2
3 defense response to virus GO:0051607 9.85 IFNA1 IFNA2 IFNB1 ITGAX
4 cytokine-mediated signaling pathway GO:0019221 9.81 IFNA1 IFNA2 IL3 IL3RA
5 B cell differentiation GO:0030183 9.79 IFNA1 IFNA2 IFNB1
6 type I interferon signaling pathway GO:0060337 9.78 IFNA1 IFNA2 IFNB1
7 positive regulation of T cell proliferation GO:0042102 9.77 ANXA1 IL2 IL2RA
8 humoral immune response GO:0006959 9.73 IFNA1 IFNA2 IFNB1
9 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 IFNA2 IL2 IL3
10 B cell proliferation GO:0042100 9.67 IFNA1 IFNA2 IFNB1
11 response to exogenous dsRNA GO:0043330 9.65 IFNA1 IFNA2 IFNB1
12 regulation of T cell differentiation GO:0045580 9.62 ADA BRAF
13 response to vitamin E GO:0033197 9.62 ADA CCND1
14 regulation of type I interferon-mediated signaling pathway GO:0060338 9.61 IFNA1 IFNA2 IFNB1
15 negative regulation of T cell differentiation GO:0045581 9.58 IFNA2 IFNB1
16 alpha-beta T cell differentiation GO:0046632 9.58 ANXA1 BRAF
17 regulation of axon regeneration GO:0048679 9.57 BRAF MAP2K1
18 negative regulation of inflammatory response GO:0050728 9.56 ACP5 ADA IL2 IL2RA
19 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2 IL2RA
20 T cell activation involved in immune response GO:0002286 9.54 IFNA1 IFNA2 IFNB1
21 positive regulation of peptidyl-serine phosphorylation of STAT protein GO:0033141 9.5 IFNA1 IFNA2 IFNB1
22 regulation of T cell homeostatic proliferation GO:0046013 9.46 IL2 IL2RA
23 negative regulation of T-helper 2 cell cytokine production GO:2000552 9.4 IFNA2 IFNB1
24 positive regulation of T cell differentiation GO:0045582 9.33 ADA IL2 IL2RA
25 natural killer cell activation involved in immune response GO:0002323 9.13 IFNA1 IFNA2 IFNB1
26 MAPK cascade GO:0000165 9.1 BRAF IL2 IL2RA IL3 IL3RA MAP2K1

Molecular functions related to Hairy Cell Leukemia according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.56 IL2 IL2RA IL3 IL3RA
2 cytokine activity GO:0005125 9.35 IFNA1 IFNA2 IFNB1 IL2 IL3
3 cytokine receptor binding GO:0005126 9.33 IFNA1 IFNA2 IFNB1
4 type I interferon receptor binding GO:0005132 8.8 IFNA1 IFNA2 IFNB1

Sources for Hairy Cell Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....